Morgan Stanley
MS
$214.20
+3.25%
Morgan Stanley is a global financial services firm operating across investment banking, institutional securities, wealth management, and investment management, with offices in 42 countries and over 83,000 employees. The firm is a market leader in wealth and asset management, boasting $9.3 trillion in client assets, and maintains a top-tier investment banking franchise. Currently, the stock is in focus as the company benefits from a rebound in capital markets activity, strong wealth management inflows, and successful cost management, while investors debate the sustainability of its growth amid a volatile macroeconomic environment and potential regulatory shifts.…
MS
Morgan Stanley
$214.20
Related headlines
Investment Opinion: Should I buy MS Today?
We rate Morgan Stanley a Buy, driven by its strong revenue growth, improving profitability, and attractive valuation relative to growth. The analyst consensus of Buy with an average target of $236.62 supports this view, implying 10.5% upside. The thesis is anchored on the firm's ability to sustain double-digit revenue growth and expand margins, leveraging its wealth management franchise.
Sign up to view all
MS 12-Month Price Forecast
The AI assessment is bullish, driven by strong fundamental momentum and attractive valuation. The stock's growth trajectory, improving margins, and analyst support outweigh the risks of high leverage and market volatility. However, the medium confidence reflects uncertainty around macro conditions and the sustainability of growth. An upgrade to high confidence would require sustained revenue growth above 15% and stable margins, while a downgrade would occur if growth decelerates below 10% or if the stock breaks below its 50-day moving average.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Morgan Stanley's 12-month outlook, with a consensus price target around $236.62 and implied upside of +10.5% versus the current price.
Average Target
$236.62
0 analysts
Implied Upside
+10.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$184 - $262
Analyst target range
Morgan Stanley is covered by 21 analysts, with a consensus recommendation of 'Buy' and a mean rating of 2.32 (where 1 is Strong Buy and 5 is Sell). The average price target is $236.62, implying an upside of 10.5% from the current price of $214.20. The distribution of ratings is not provided, but the consensus leans bullish. The target price range is from $184.00 (low) to $262.00 (high), with the high target implying a 22.3% upside and the low target implying a 14.1% downside. The wide spread of $78 between low and high targets indicates significant uncertainty about the stock's future performance. Recent ratings actions have been mixed, with UBS and B of A maintaining Buy ratings, while Oppenheimer downgraded from Perform to Underperform in June 2026. This divergence reflects differing views on the sustainability of the firm's earnings growth and the impact of market conditions on its businesses.
Bulls vs Bears: MS Investment Factors
Morgan Stanley presents a compelling growth story with strong revenue acceleration, margin expansion, and a dominant wealth management franchise. The bull case is supported by a PEG of 0.60 and analyst consensus Buy with 10.5% upside. However, the bear case highlights high leverage, negative FCF, and a valuation premium to peers. Currently, the bull case has stronger evidence given the robust earnings momentum and improving profitability, but the key tension is whether the firm can sustain its growth trajectory amid market volatility and regulatory changes. The stock's performance hinges on continued capital markets activity and wealth management inflows, which could shift the thesis either way.
Bullish
- Strong Revenue Growth: Q2 2026 revenue surged 22.4% YoY to $34.47B, with sequential acceleration from $28.86B in Q4 2025. This growth is broad-based across wealth management, institutional securities, and investment management, indicating robust demand for financial services.
- Improving Profitability: Net margin expanded to 16.2% in Q2 2026 from 12.6% a year ago, while operating margin rose to 21.5% from 16.4%. This reflects successful cost management and a favorable revenue mix, driving higher earnings conversion.
- Undervalued on PEG: With a PEG ratio of 0.60, the stock is trading at a discount to its growth rate. This suggests the market is not fully pricing in the expected earnings growth, offering upside potential for investors.
- Analyst Consensus Buy: 21 analysts rate MS a 'Buy' with a mean rating of 2.32, and the average price target of $236.62 implies 10.5% upside from the current price. This indicates broad institutional support for the stock.
Bearish
- High Leverage Risk: Debt-to-equity ratio of 4.26 is typical for banks but amplifies risk in downturns. A 1% adverse move in asset values could significantly impact equity, making the stock sensitive to credit market stress.
- Negative Free Cash Flow: TTM free cash flow is -$1.05B, indicating the firm is consuming cash due to working capital swings and investments. This could limit capital return flexibility and signal underlying cash flow strain.
- Valuation Premium to Peers: Trailing PE of 17.17x is 14% above the industry average of 15x. While justified by growth, any earnings miss could trigger multiple compression, especially if growth decelerates.
- Market Volatility Exposure: Beta of 1.209 means the stock is 21% more volatile than the market. Recent 1-month decline of -1.97% despite a 3-month gain shows sensitivity to market swings, which could lead to sharp drawdowns.
MS Technical Analysis
Morgan Stanley's stock has been in a strong uptrend over the past year, with a 1-year price change of +48.7%, significantly outperforming the S&P 500's +20.5% gain. The current price of $214.20 is near the upper end of its 52-week range, sitting at approximately 92% of the range (calculated as (214.20 - 144.67) / (232.25 - 144.67) = 79.5% actually, but let's correct: (214.20-144.67)/(232.25-144.67)=69.53/87.58=79.4% of the range). This positioning near the highs suggests strong momentum, though it also raises the risk of overextension. The stock has pulled back from its 52-week high of $232.25, indicating some profit-taking after a strong run.
Beta
1.21
1.21x market volatility
Max Drawdown
-19.3%
Largest decline past year
52-Week Range
$146-$232
Price range past year
Annual Return
+48.7%
Cumulative gain past year
| Period | MS Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | +3.6% |
| 3m | +6.6% | +2.7% |
| 6m | +22.1% | +11.4% |
| 1y | +48.7% | +18.7% |
| ytd | +17.8% | +12.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MS Fundamental Analysis
Morgan Stanley's revenue has been growing robustly, with the most recent quarter (Q2 2026) reporting revenue of $34.47 billion, a 22.4% increase year-over-year. This growth is accelerating, as seen in the sequential trend: Q1 2026 revenue was $33.15 billion, Q4 2025 was $28.86 billion, and Q3 2025 was $30.05 billion. The growth is broad-based, with Wealth Management contributing $8.43 billion, Institutional Securities $7.93 billion, and Investment Management $1.72 billion in the latest quarter. The firm's profitability is strong, with net income of $5.58 billion in Q2 2026, up from $3.54 billion in the year-ago quarter, and a net margin of 16.2%. Gross margin expanded to 61.6% from 54.7% a year ago, reflecting improved revenue mix and cost discipline. Operating margin also improved to 21.5% from 16.4% in Q2 2025. The balance sheet is highly leveraged, with a debt-to-equity ratio of 4.26, typical for a bank, but the firm maintains a strong liquidity position with $133.5 billion in cash at the end of Q1 2026. However, free cash flow has been negative in recent quarters, with TTM FCF of -$1.05 billion, due to working capital swings and investment activities. ROE stands at 15.1%, which is solid for a financial institution, and the firm has a current ratio of 1.17, indicating adequate short-term liquidity.
Quarterly Revenue
$34.5B
2026-06
Revenue YoY Growth
+22.4%
YoY Comparison
Gross Margin
61.7%
Latest Quarter
Free Cash Flow
$-1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MS Overvalued?
Given that Morgan Stanley is profitable, the PE ratio is the primary valuation metric. The trailing PE is 17.17x, while the forward PE is 15.71x, indicating that the market expects earnings growth. The gap between trailing and forward PE suggests an expected earnings increase of about 9% over the next year. Compared to the industry average PE of 15x (based on available data), Morgan Stanley trades at a 14% premium, which is justified by its superior growth and profitability. The PEG ratio of 0.60 suggests the stock is undervalued relative to its growth rate. Historically, the stock's PE has ranged from about 10.7x to 27.1x over the past few years, with the current 17.17x sitting in the middle of that range. This suggests the stock is not overvalued relative to its own history, and the market is pricing in moderate growth expectations.
PE
17.2x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 11x~17x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
24.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks are significant due to Morgan Stanley's high leverage, with a debt-to-equity ratio of 4.26, typical for banks but amplifying downside in credit stress. The negative free cash flow of -$1.05B TTM indicates cash consumption from working capital and investments, which could constrain capital returns. Revenue concentration in capital markets and wealth management exposes the firm to cyclical downturns, as seen in Q2 2025 when revenue was $28.16B, 18% below the latest quarter. Earnings volatility is inherent, with net income swinging from $3.54B in Q2 2025 to $5.58B in Q2 2026, reflecting market-dependent performance.
FAQ
The key risks include: 1) High leverage (D/E 4.26) which amplifies losses in downturns, 2) Negative free cash flow of -$1.05B TTM, which could limit capital returns, 3) Market volatility with a beta of 1.209, making the stock more sensitive to market swings, and 4) Regulatory changes that could impact capital requirements or trading activities. The most severe risk is a market downturn that could reduce investment banking and trading revenues, potentially leading to a 32.5% decline to the 52-week low of $144.67.
The 12-month forecast is moderately bullish, with a base case target of $236.62 (10.5% upside) and a bull case target of $262 (22.3% upside). The bear case target is $184 (14.1% downside). The base case has a 50% probability, assuming continued revenue growth and stable margins. The bull case (30% probability) requires robust capital markets activity, while the bear case (20% probability) would be triggered by a market downturn. Overall, the most likely scenario is a gradual appreciation toward the average target.
MS is trading at a trailing PE of 17.17x, which is 14% above the industry average of 15x, indicating a premium. However, the forward PE of 15.71x suggests expected earnings growth, and the PEG ratio of 0.60 implies the stock is undervalued relative to its growth rate. Historically, the PE has ranged from 10.7x to 27.1x, and the current level is in the middle, suggesting it is not overvalued. The market is pricing in moderate growth expectations, and if the company delivers on its growth trajectory, the valuation is justified.
MS is a good buy for investors seeking exposure to a leading financial services firm with strong growth prospects. The stock offers a 10.5% upside to the average analyst target of $236.62, and the PEG ratio of 0.60 suggests it is undervalued relative to its growth rate. However, the high leverage (D/E 4.26) and negative FCF pose risks, so it is best suited for investors with a higher risk tolerance. For those with a long-term horizon, the stock's strong wealth management franchise and improving profitability make it an attractive addition to a diversified portfolio.
MS is suitable for both long-term and short-term investment, but it is better suited for long-term investors given its growth potential and wealth management stability. The stock has a beta of 1.209, indicating higher volatility, which can be advantageous for short-term traders but also risky. With a dividend yield of 2.36% and a payout ratio of 39.1%, it provides some income. For long-term investors, a minimum holding period of 3-5 years is recommended to ride out market cycles and benefit from the firm's growth. Short-term traders should be aware of the stock's sensitivity to market news and earnings reports.